Because recent evidence suggests that secondary inflammation and caspase activation may contribute to neurodegeneration in ALS, we tested the effects of minocycline, a second-generation tetracycline with anti-inflammatory properties, in mice expressing a mutant superoxide dismutase (SOD1 G37R ) linked to human ALS. Administration of minocycline into the diet, beginning at late presymptomatic stage (7 or 9 months of age), delayed the onset of motor neuron degeneration, muscle strength decline, and it increased the longevity of SOD1 G37R mice by ϳ5 weeks for ϳ70% of tested mice. Moreover, less activation of microglia was detected at early symptomatic stage (46 weeks) and at the end stage of disease in the spinal cord of SOD1 G37R mice treated with minocycline. These results indicate that minocycline, which is clinically well tolerated, may represent a novel and effective drug for treatment of ALS.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a late onset neurodegenerative disease characterized by progressive muscle weakness, muscle atrophy and eventual paralysis, leading to death within 2-5 years (Cleveland, 1999; Julien, 2001; Rowland et al., 2001) . The vast majority of ALS cases are sporadic with no known genetic component. Familial forms of ALS (FALS), being inherited in an autosomal dominant pattern, make up ϳ10% of all ALS cases. In 20% of FALS, missense mutations have identified in the gene coding for superoxide dismutase 1 (SOD1) (Rosen et al., 1993; Cudkowicz et al., 1997) . To date, over 90 mutations have been discovered spanning all exons of the SOD1 gene. In cases having the form known as type 3 autosomal recessive ALS, deletion mutations have recently been discovered in coding exons of a new gene mapping to chromosome 2q33, called ALS2 (Hadano et al., 2001; Yang et al., 2001) . The ALS2 gene is ubiquitously expressed and it encodes a protein having multiple motifs with homology to guanine-nucleotide exchange factors.
Transgenic mice overexpressing SOD1 mutants linked to FALS develop progressive motor neuron disease with many pathological features observed in both familial and sporadic ALS cases (Gurney et al., 1994; Wong et al., 1995; Bruijn et al., 1998 ). Yet, the mechanism of SOD1-mediated disease is not fully understood. Recent studies suggest that the toxicity of SOD1 mutants could result from the propensity of misfolded protein mutants to form cytoplasmic aggregates that may interfere with normal cellular functions (Bruijn et al., 1998; Cleveland, 1999; Julien, 2001) . The current view is that the motor neuron death in ALS is complex and may involve multiple pathways including formation of protein aggregates, proteosome dysfunction, axonal transport defects, oxidative damage, mitochondrial defects, alterations in calcium homeostasis, caspase activation, and changes in levels of Bcl-2 members (Julien, 2001; Rowland et al., 2001) . In addition, excitotoxicity due to astrocyte dysfunction and inflammatory processes from microglia activation are other nonneuronal events likely to be involved in the propagation of the neurodegenerative process (Kawamata et al., 1992; Trooost et al., 1993 
